Microsample Prep Company IntegenX Inc. Raises $15.6M, Acquires GenVault Corporation
News Feb 07, 2011
IntegenX Inc. (IXI) has announced the close of a transaction that included acquiring substantially all the stock of GenVault Corporation and a $15.6M round of financing led by Domain Associates with participation from returning investors. The capital will fund the commercialization of the Apollo 324 System for next-generation sequencing library preparation, the development of the Apollo 200 RapidHIT™ System for DNA-based human identification and the world-wide marketing of the GenTegra™ product line.
The addition of GenVault's products to the IntegenX portfolio allows IntegenX to offer products that will make transportation and storage of user samples easier without needing refrigeration and without allowing degradation. The GenTegra™ products are now a part of IntegenX's "sample-to-answer" process control and will increase the quality and value of data produced by IntegenX's integrated sample preparation systems.
"As more and more genetic samples are stored and prepared for analysis, the potential for losing sample integrity while waiting for chemistry preparation increases," said Stevan Jovanovich, Ph.D., President and Chief Executive Officer of IntegenX. "This affects data quality and is therefore an acute issue for nucleic acid sample preparation. The GenVault products address this problem successfully by stabilizing both RNA and DNA for next-generation sequencing, genotyping, forensic analysis, and other genomic applications," he added.
The financing was led by life science venture capital firm Domain Associates, with participation from previous investors In-Q-Tel and RONAholdings LLC. With the transaction announced today, GenVault investors QuestMark Partners, Cross Creek Partners, and Greenspring Associates join the syndicate backing IntegenX.
"The management team at IntegenX has brought more than 40 products to market over the past 20 years at Applied Biosystems, Molecular Dynamics, Amersham, and other successful companies," said Jim Blair, Ph.D., founding partner at Domain Associates. "By focusing on system integration and sample preparation, IntegenX has built a valuable portfolio of products for sequencing and human identification that are needed in the market right now."
Ancient Fish Genes May Hold Key to Spinal Cord RepairNews
A study has found that genes controlling spinal cord repair in the lamprey fish are also active in mammals, which could provide a blueprint for treatment.READ MORE
Prostate Tumor Progression Dictated by Cancer’s Gene-determined “Immune Landscape”News
The field of immunotherapy is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of patients, suggesting that as-yet unidentified variations among tumors result in distinct paths of disease progression and response to therapy.READ MORE